As part of our mission to deliver the latest medical breakthroughs, the Chan Soon-Shiong Institute for Medicine, Immuno-Oncology Network physicians conduct clinical trials that test new treatments for different patients and cancer types. The following trials are coming soon to Chan Soon-Shiong Institute for Medicine at Mariposa.

Open-label, Phase 1 Study of haNK® for Infusion in Subjects With Metastatic or
Locally Advanced Solid Tumors
https://clinicaltrials.gov/ct2/show/NCT03027128
Indication: Solid Tumors
NCT03027128 | QUILT-3.028

NANT Triple Negative Breast Cancer (TNBC) Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects with TNBC Who Have Progressed on or After Standard-of-care Therapy
https://clinicaltrials.gov/ct2/show/NCT03387085
Indication: Triple Negative Breast Cancer
NCT03387085 | QUILT-3.067

NANT Squamous Cell Carcinoma (SCC) Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects with SCC Who Have Progressed on or After Platinum-based Chemotherapy and Anti-programmed Cell Death Protein 1 (PD-1)/Programmed Death-ligand 1 (PD-L1) Therapy
https://clinicaltrials.gov/ct2/show/NCT03387111
Indication: Squamous Cell Carcinoma
NCT03387111 | QUILT-3.090

A Phase 1B/2 Trial of the NANT Pancreatic Cancer Vaccine as Treatment for Subjects with Pancreatic Cancer Who Have Progressed On Or After Standard-of-care Therapy
https://clinicaltrials.gov/ct2/show/NCT03586869
Indications: Pancreatic Cancer
NCT number: pending | QUILT 3.080

A NANT Colorectal Cancer (CRC) Vaccine: A phase 1b/2 Trial of the NANT CRC Vaccine vs Regorafenib in Subjects with Metastatic CRC Who Have Been Previously Treated with Standard-of-Care Therapy
https://clinicaltrials.gov/ct2/show/NCT03563157
Indication: Colorectal Cancer
NCT03563157 | QUILT 3.071

A NANT Hepatocellular Carcinoma (HCC) Vaccine: Molecularly Informed Integrated Immunotherapy Combining Innate High-affinity Natural Killer (haNK) Cell Therapy w/ Adenoviral & Yeast-based Vaccines to Induce T-cell Responses in Subjects w/ Advanced, Unresectable & Untransplantable HCC
https://clinicaltrials.gov/ct2/show/NCT03563170
Indication: Hepatocellular Carcinoma Non-resectable, Hepatocellular Carcinoma Recurrent
NCT03563170 | QUILT 3.072

A Phase 2, Open-Label, Randomized Study of ALT-803, a Fusion Protein Activator of Natural Killer and T-Cells, in Combination With Pembrolizumab vs Pembrolizumab Alone as First-Line Treatment for Patients With Metastatic NSCLC
https://clinicaltrials.gov/ct2/show/NCT03520686
Indications: Non Small Cell Lung Cancer
NCT03520686 | QUILT 2.023

A Phase IIb, Single-Arm, Open-Label Study of ALT-803 in Combination With Pembrolizumab or Nivolumab in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Disease Progression Following an Initial Response to Treatment With PD-1 Checkpoint Inhibitor Therapy
https://clinicaltrials.gov/ct2/show/NCT03228667
Indications: Non-Small Cell Lung Cancer
NCT03228667 | QUILT 3.055

A Phase 1 Trial of ABI-011 Administered Weekly in Patients with Advanced Solid Tumors or Lymphomas
https://clinicaltrials.gov/ct2/show/NCT02582827
Indication: Solid Tumors and Lymphomas
NCT02582827 | QUILT-3.014

A Phase 2 Study of AMG 337 in Subjects with Advanced or Metastatic Clear Cell Sarcoma that Contains the EWSR1-ATF1 Gene Fusion
https://clinicaltrials.gov/ct2/show/NCT03132155
Indication: Clear Cell Sarcoma
NCT03132155 | QUILT-3.031

A Phase 2 Study of AMG 337 in Subjects with Advanced or Metastatic Solid Tumors that Overexpress MET or Harbor MET EXON 14Skipping (METEX14DEL) Mutations
https://clinicaltrials.gov/ct2/show/NCT03147976
Indication: Solid Tumors
NCT03147976 | Quilt-3.036

Phase I Study of Ad5 [E1-, E2b-]-HER2/Neu Vaccine (ETBX-021) in Subjects With Unresectable Locally Advanced or Metastatic HER2-Low-Expressing (IHC 1+/2+) Breast Cancer
https://clinicaltrials.gov/ct2/show/NCT02751528
Indications: HER2-low expressing (IHC 1+ or 2+) breast cancer
NCT02751528 | QUILT 3.013

An Open-label, Single-arm, Phase 1b/2 Study of NANT-008 in Combination With 5-fluorouracil, Bevacizumab, Leucovorin, and Oxaliplatin in Patients With Metastatic Pancreatic Adenocarcinoma
https://clinicaltrials.gov/ct2/show/NCT03127124
Indications: Pancreatic Adenocarcinoma
NCT03127124 | QUILT 2.022

NANT Pancreatic Cancer Vaccine: Phase II Randomized Trial of the NANT Pancreatic Cancer Vaccine vs. Standard-of-Care as First- Line Treatment for Patients With Metastatic Pancreatic Cancer
https://clinicaltrials.gov/ct2/show/NCT03563144
Indications: Pancreatic Cancer
NCT03563144 | QUILT 3.088